echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bayer's cell therapy for advanced Parkinson's disease obtains FDA fast-track qualification

    Bayer's cell therapy for advanced Parkinson's disease obtains FDA fast-track qualification

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 19, 2021, BlueRock (BlueRock Therapeutics), a clinical trial stage biopharmaceutical company wholly-owned by the Bayer Group, announced that the U.


    The FDA’s fast-track qualification is designed to promote the development and speed up the approval process of new therapies for treating serious diseases and filling unmet medical needs


    The trial will recruit 10 patients in the United States and Canada


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.